Basics Innoviva, Inc. Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines. The firm collaborates with and receives funding from GlaxoSmithKline. IPO Date: November 25, 2008 Sector: Healthcare Industry: Pharma Market Cap: $1.1B Activated in VL: True Average Daily Range Avg Daily Range: $0.20 | 1.46% Avg Daily Range (30 D): $0.27 | 1.49% Avg Daily Range (90 D): $0.25 | 1.28% Institutional Daily Volume Avg Daily Volume: .64M Avg Daily Volume (30 D): .59M Avg Daily Volume (90 D): .6M Trade Size Avg Trade Size (Sh.): 95 Avg Trade Size (Sh.) (30 D): 51 Avg Trade Size (Sh.) (90 D): 53 Institutional Trades Total Inst.Trades: 4,321 Avg Inst. Trade: $1.76M Avg Inst. Trade (30 D): $2.37M Avg Inst. Trade (90 D): $2.46M Avg Inst. Trade Volume: .12M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.79M Avg Closing Trade (30 D): $2.8M Avg Closing Trade (90 D): $3.01M Avg Closing Volume: 120.76K     News Aug 7, 2025 @ 3:17 AM Innoviva (INVA) Q2 Sales Jump 64% Source: Na Dec 16, 2024 @ 6:15 AM Basilea announces agreement with Innoviva Specialt... Source: N/A Jun 18, 2024 @ 5:44 PM Analyst Projects Strong Growth for GSK-Innoviva Pa... Source: Vandana Singh Mar 2, 2024 @ 3:29 PM 10 stocks you can bet on being inflation-proof Source: MarketWatch May 24, 2023 @ 2:32 AM FDA approves Innoviva’s bacterial pneumonia... Source: MarketWatch Financials   TTM Q2 2025 Q1 2025 Basic EPS $.61 $1.01 $-.74 Diluted EPS $.57 $.77 $-.74 Revenue $ 370.23M $ 100.28M $ 88.63M Gross Profit $ $ 83.15M $ 73.32M Net Income / Loss $ 38.65M $ 63.69M $ -46.58M Operating Income / Loss $ 121.72M $ 48.75M $ 41.43M Cost of Revenue $ $ 17.14M $ 15.32M Net Cash Flow $ 180.53M $ 78.44M $ 14.13M PE Ratio 0.00     Splits Jun 17, 2013:   1:100